Dublin, Jan. 22, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/wk7n9x/gene_therapy) has announced the addition of Jain PharmaBiotech's new report "Gene Therapy - Technologies, Markets and Companies" to their offering.
Gene therapy markets are estimated for the years 2015-2025. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright.The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets
The voluminous literature on gene therapy was reviewed and selected 750 references are appended in the bibliography.The references are constantly updated. The text is supplemented with 75 tables and 18 figures.
Profiles of 186 companies involved in developing gene therapy are presented along with 229 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold within a decade. These companies have been followed up since they were the topic of a book on gene therapy companies by the author of this report. John Wiley & Sons published the book in 2000 and from 2001 to 2003, updated versions of these companies (approximately 160 at mid-2003) were available on Wiley's web site. Since that free service was discontinued and the rights reverted to the author, this report remains the only authorized continuously updated version on gene therapy companies.
Key Topics Covered:
Part I: Technologies & Markets
Executive Summary
1. Introduction
2. Gene Therapy Technologies
3. Clinical Applications of Gene Therapy
4. Gene Therapy of Genetic Disorders
5. Gene Therapy of Cancer
6. Gene Therapy of Neurological Disorders
7. Gene Therapy of Cardiovascular Disorders
8. Gene therapy of viral infections
9. Research, Development and Future of Gene Therapy
10. Regulatory, Safety and Ethical Issues of Gene Therapy
11. Markets for Gene Therapy
12. References
Part II: Companies
13. Companies involved in Gene Therapy
For more information visit http://www.researchandmarkets.com/research/wk7n9x/gene_therapy
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Genomics, Genomics


Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Robinhood Expands Sports Event Contracts With Player Performance Wagers
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Shell M&A Chief Exits After BP Takeover Proposal Rejected 



